← SynDRA
MIFEPRISTONE
SynDRA canonical compound SYN0024851 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PGR |
|---|
| Mechanism of action | Glucocorticoid receptor antagonist |
|---|
| Indication | diabetes mellitus | hyperglycemia |
|---|
| Disease area | endocrinology |
|---|
All known targets
- NR3C1
- PGR
- AR
- NR1I2
- ADRA2B
- FYN
- Pgr
- OPRM1
- OPRK1
- NR3C2
- MAPK14
- ESR2
Mechanisms of action (all sources)
- PGR ANTAGONIST
- NR3C1 ANTAGONIST
- NR3C1 MODULATOR
Drug classes
- Progestational Hormone Receptor Antagonists
- Progestin Antagonist
- Abortifacient Agents
- Abortifacient Agents, Steroidal
- Contraceptive Agents
- Contraceptive Agents, Female
- Contraceptive Agents, Hormonal
- Contraceptives, Oral, Synthetic
- Contraceptives, Postcoital, Synthetic
- Hormone Antagonists
- Luteolytic Agents
- Menstruation-Inducing Agents
ATC classes
- G03X · OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Cross-references
Synonyms
- mifegyne
- mifeprex
- mifestone
- Mifepristona
- NSC-759862
- RU-38486
- RU-486
- RU486
- Korlym
- Mifegyne
- Mifeprex
- Mifedren
- HRA-052015
- Mifepristone (Cushing's disease)
- ACTH modulator (Cushing's disease), HRA
- Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma
- Mifepristone (Cushing's disease), HRA pharma
- RU 486
- Mifepriston
- Corlux
- C29H35NO2
- MLS000069785
- 320T6RNW1F
- VGX-410C
- CHEBI:50692
- VGX-410
- NSC 759862
- NCGC00025179-05
- SMR000058481
- Mifepristonum [Latin]
- Mifepristona [Spanish]
- C-1073
- (11beta,17beta)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one
- (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
- (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
- (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
- 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
- Mifepristonum
Reported adverse events
- Infection
- Dizziness
- Headache
- Nausea
- Vomiting
- Adrenal insufficiency
- Angioedema
- Arthralgia
- Back pain
- Blood potassium decreased
- Constipation
- Dry mouth
Look up MIFEPRISTONE in the interactive SynDRA portal →